Related Experiment Video

Updated: Jun 21, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Predicting the future of anti-tumor necrosis factor therapy

Cornelis L Verweij

    Arthritis Research & Therapy
    |July 14, 2009
    PubMed

    Insights

    Identifying responders and non-responders to tumor necrosis factor (TNF) antagonists for rheumatoid arthritis (RA) is crucial. A new multi-parameter serum biomarker set shows predictive value for anti-TNF treatment success, enabling personalized medicine approaches.

    Area of Science:

    • Biomarkers
    • Rheumatoid Arthritis
    • Immunotherapy

    Background:

    • Tumor necrosis factor (TNF) antagonists are widely used for rheumatoid arthritis (RA) treatment.
    • However, only about two-thirds of patients respond to TNF-blocking therapy, necessitating predictive markers.
    • Predicting treatment success is vital due to RA's destructive nature, potential adverse effects, and therapy costs.

    Discussion:

    • Hueber and colleagues introduce a novel multi-parameter serum protein biomarker set.
    • This set demonstrates predictive capability for anti-TNF treatment outcomes before therapy initiation.
    • This represents a significant advancement in identifying potential responders and non-responders.

    Key Insights:

    • A multi-parameter serum protein biomarker set can predict anti-TNF treatment response in rheumatoid arthritis.
    • This biomarker set offers a tool to personalize rheumatoid arthritis therapy selection.
    • Early prediction of treatment success can optimize patient management and resource allocation.

    Outlook:

    • The identified biomarker set may pave the way for personalized medicine in rheumatoid arthritis.
    • Future research could validate and refine these biomarkers for clinical application.
    • This approach could lead to more effective and individualized treatment strategies for RA patients.

    More Related Videos

    Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method16:07

    Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

    Published on: September 16, 2017

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

    Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

    Published on: January 19, 2019

    Related Concept Videos

    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

    Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

    Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...